MBX Biosciences (MBX) Competitors $10.83 +0.90 (+9.06%) As of 09/12/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFDA EventsSEC FilingsShort InterestTrendsBuy This Stock MBX vs. VERA, AVDL, COGT, SNDX, JANX, SDGR, HROW, AMPH, NUVB, and WVEShould you be buying MBX Biosciences stock or one of its competitors? The main competitors of MBX Biosciences include Vera Therapeutics (VERA), Avadel Pharmaceuticals (AVDL), Cogent Biosciences (COGT), Syndax Pharmaceuticals (SNDX), Janux Therapeutics (JANX), Schrodinger (SDGR), Harrow (HROW), Amphastar Pharmaceuticals (AMPH), Nuvation Bio (NUVB), and WAVE Life Sciences (WVE). These companies are all part of the "pharmaceutical products" industry. MBX Biosciences vs. Its Competitors Vera Therapeutics Avadel Pharmaceuticals Cogent Biosciences Syndax Pharmaceuticals Janux Therapeutics Schrodinger Harrow Amphastar Pharmaceuticals Nuvation Bio WAVE Life Sciences MBX Biosciences (NASDAQ:MBX) and Vera Therapeutics (NASDAQ:VERA) are both small-cap pharmaceutical products companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, analyst recommendations, earnings, profitability, media sentiment, institutional ownership and valuation. Do insiders & institutionals believe in MBX or VERA? 99.2% of Vera Therapeutics shares are owned by institutional investors. 52.2% of MBX Biosciences shares are owned by company insiders. Comparatively, 16.3% of Vera Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Do analysts rate MBX or VERA? Vera Therapeutics has a consensus price target of $63.00, indicating a potential upside of 165.04%. Given Vera Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Vera Therapeutics is more favorable than MBX Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MBX Biosciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Vera Therapeutics 0 Sell rating(s) 2 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.90 Is MBX or VERA more profitable? MBX Biosciences' return on equity of -31.33% beat Vera Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets MBX BiosciencesN/A -31.33% -29.96% Vera Therapeutics N/A -46.70%-39.46% Does the media prefer MBX or VERA? In the previous week, Vera Therapeutics had 8 more articles in the media than MBX Biosciences. MarketBeat recorded 9 mentions for Vera Therapeutics and 1 mentions for MBX Biosciences. Vera Therapeutics' average media sentiment score of 1.44 beat MBX Biosciences' score of 0.35 indicating that Vera Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MBX Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Vera Therapeutics 7 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has stronger earnings & valuation, MBX or VERA? Vera Therapeutics is trading at a lower price-to-earnings ratio than MBX Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMBX BiosciencesN/AN/A-$61.92M-$4.54-2.39Vera TherapeuticsN/AN/A-$152.15M-$3.58-6.64 SummaryVera Therapeutics beats MBX Biosciences on 8 of the 13 factors compared between the two stocks. Get MBX Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for MBX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MBX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MBX vs. The Competition Export to ExcelMetricMBX Biosciences IndustryManufacturing SectorNASDAQ ExchangeMarket Cap$333.59M$2.39B$2.57B$10.14BDividend YieldN/A13.81%2.52%4.60%P/E Ratio-2.3925.6726.5525.98Price / SalesN/A11,662.77104.16181.13Price / CashN/A20.0049.2160.44Price / Book1.413.5934.656.29Net Income-$61.92M-$411.68M$16.40M$271.07M7 Day Performance-6.23%1.14%1.86%3.87%1 Month PerformanceN/A1.64%3.68%4.88%1 Year PerformanceN/A11.16%35.86%26.12% MBX Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MBXMBX Biosciences0.1435 of 5 stars$10.83+9.1%N/AN/A$333.59MN/A-2.39N/ANews CoverageAnalyst UpgradeHigh Trading VolumeVERAVera Therapeutics3.044 of 5 stars$24.19+10.5%$63.00+160.4%-33.3%$1.54BN/A-6.7640Positive NewsAVDLAvadel Pharmaceuticals2.898 of 5 stars$15.76+5.1%$20.86+32.3%+10.4%$1.53B$169.12M-525.3370Positive NewsCOGTCogent Biosciences2.8671 of 5 stars$13.05+0.9%$20.00+53.3%+23.3%$1.49BN/A-7.3380Positive NewsSNDXSyndax Pharmaceuticals3.9113 of 5 stars$17.04+5.3%$38.89+128.2%-13.6%$1.47B$23.68M-4.38110Analyst ForecastJANXJanux Therapeutics2.4948 of 5 stars$23.98+0.2%$85.55+256.7%-48.3%$1.44B$10.59M-13.3230News CoveragePositive NewsAnalyst ForecastSDGRSchrodinger3.3918 of 5 stars$19.13+0.8%$27.83+45.5%-9.8%$1.41B$237.92M-7.71790HROWHarrow3.0768 of 5 stars$36.99+2.2%$64.67+74.8%-6.3%$1.37B$227.66M-147.96180Trending NewsAnalyst RevisionGap UpAMPHAmphastar Pharmaceuticals3.8618 of 5 stars$29.42+0.8%$31.60+7.4%-39.7%$1.37B$731.97M11.022,028Positive NewsNUVBNuvation Bio2.602 of 5 stars$3.88+13.5%$7.33+89.0%+3.0%$1.33B$7.87M-6.1660High Trading VolumeWVEWAVE Life Sciences4.5542 of 5 stars$8.29+1.3%$20.07+142.1%+18.9%$1.32B$108.30M-9.21240Positive News Related Companies and Tools Related Companies VERA Competitors AVDL Competitors COGT Competitors SNDX Competitors JANX Competitors SDGR Competitors HROW Competitors AMPH Competitors NUVB Competitors WVE Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MBX) was last updated on 9/13/2025 by MarketBeat.com Staff From Our PartnersWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredOctober 16 Changes the Microchip Game — and InvestingWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MBX Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MBX Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MBX Stock Alerts